Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionHB Wealth Management, LLC
Latest Disclosed Ownership3,436 shares
Latest Disclosed Value $ 2,655,395
HB Wealth Management, LLC reports 41.57% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 27, 2026 - HB Wealth Management, LLC filed a 13F-HR form disclosing ownership of 3,436 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $2,655,395 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 28, 2026 disclosing 2,427 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 41.57% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,436 1,009 41.57 2,655 41.68 0.0172
2026-01-28 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,427 646 36.27 1,874 87.21 0.0121
2025-10-23 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,781 -268 -13.08 1,002 -6.88 0.0068
2025-07-17 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,049 46 2.30 1,076 -15.35 0.0086
2025-05-07 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,003 -126 -5.92 1,270 -16.23 0.0106
2025-01-15 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,129 161 8.18 1,516 -26.69 0.0155
2024-10-15 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,968 116 6.26 2,069 6.27 0.0222
2024-07-26 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,852 181 10.83 1,947 21.02 0.0227
2024-04-30 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,671 552 49.33 1,608 63.75 0.0202
2024-01-16 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,119 212 23.37 983 31.64 0.0141
2023-10-13 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 907 199 28.11 746 46.85 0.0121
2023-07-13 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 708 6 0.85 509 -11.81 0.0081
2023-04-13 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 702 154 28.10 577 45.82 0.0100
2023-01-20 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 548 135 32.69 395 38.60 0.0072
2022-10-19 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 413 413 285 0.0061
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.